Avience Biomedicals Limited
ListedSMEHealthcare · NSE
Incorporated in June 2024, Avience Biomedicals Limited is an ISO-certified company engaged in the manufacturing, supply, and export of molecular diagnostic solutions for the biotechnology, genomics, and in-vitro diagnostics (IVD) sectors. The company offers a wide range of healthcare products, including rapid test kits, molecular diagnostic kits, biochemistry and hematology analyzers, medical devices, and diagnostic reagents. Its products serve pathology laboratories, hospitals, microbiology labs, and research centers in India and overseas. Along with manufacturing, the company also operates as a distributor and trader of medical equipment. Its manufacturing facility is located in Noida, Uttar Pradesh. As of January 31, 2026, Avience Biomedicals had 75 permanent employees and 33 contractual employees.
Price Band
₹196 – ₹208
Issue Size
₹145.38 L Cr
Lot Size
600 shares
GMP
₹110
+52.9%
Est. Listing
₹318
at current GMP
Subscribed
385.40x
overall
Open
18 Jun 2026
Close
22 Jun 2026
Allotment
23 Jun 2026
Refund
24 Jun 2026
Demat Credit
25 Jun 2026
Listing
25 Jun 2026
Last updated 3 months ago
Overall Subscription
385.40x
Total Demand
QIB Multiplier
196.77x
Institutions & Funds
NII / HNI
597.63x
High Net-Worth
Retail (RII)
401.36x
Individual Bidders
Category-Wise Subscription Breakup
Live bidding breakdown by institutional, non-institutional, and retail investors
| Category | Shares Offered | Shares Applied / Bid | Times Subscribed |
|---|---|---|---|
| QIB | 273,600 | 53,837,400 | 196.77x |
| NIB | 207,000 | 123,709,800 | 597.63x |
| HNIs(10L +) | 138,000 | 92,566,800 | 670.77x |
| HNIs (2-10L) | 69,000 | 31,143,000 | 451.35x |
| RETAIL | 481,200 | 193,132,800 | 401.36x |
| Total | 1,168,800 | 494,389,800 | 385.40x |
Application-Wise Breakup
Total unique applications received across retail and HNI tranches
| Category | Applications Reserved | Applications Received | Times Subscribed |
|---|---|---|---|
| QIB | — | 172 | 0.00x |
| NIB | — | 31,836 | 0.00x |
| RETAIL | 401 | 160,944 | 401.36x |
| HNIs(10L +) | 77 | 16,492 | 214.18x |
| HNIs (2-10L) | 38 | 15,344 | 403.79x |
| Total Applications | 516 | 224,788 | 435.64x |
Day-Wise Subscription Progress
About Avience Biomedicals Limited Public Issue & Market Profile
Avience Biomedicals Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹14,53,800 Crores. The shares are offered at a price band of ₹196 to ₹208 per equity share on NSE. Currently, grey market participants and retail investors are watching the bidding trend, premium movement, and anchor book demand with keen interest.
Bidding & Quota Instructions:
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 600 shares (approx. ₹1,24,800 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment Reconciliation Schedule:
Allotment reconciliation will be managed by Skyline Financial Services Private Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2026-06-25, while un-allotted funds or UPI block mandates will be released on 2026-06-24.
Frequently Asked Questions
What is the issue size and price band for Avience Biomedicals Limited IPO?
The Avience Biomedicals Limited IPO aggregate issue size is ₹14,53,800 Crores with an equity price band set at ₹196 to ₹208 per equity share. The retail lot size is 600 shares requiring a minimum capital outlay of approx. ₹1,24,800.
How can I check Avience Biomedicals Limited IPO live subscription demand?
Live subscription figures are compiled real-time from the NSE and BSE bidding engines. You can track QIB, NII/HNI, and Retail category multiples directly on our dedicated live subscription page.
Where will Avience Biomedicals Limited IPO allotment status be published?
The basis of allotment will be published on the official registrar portal (Skyline Financial Services Private Limited) and the BSE status verification website on or around 2026-06-23.